Table of Contents
Hepatitis Research and Treatment
Volume 2013, Article ID 739247, 9 pages
http://dx.doi.org/10.1155/2013/739247
Clinical Study

Elevation in Serum Concentration of Bone-Specific Alkaline Phosphatase without Elevation in Serum Creatinine Concentration Secondary to Adefovir Dipivoxil Therapy in Chronic Hepatitis B Virus Infection

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine Katsushika Medical Center, Katsushika-ku, Tokyo 125-8506, Japan

Received 11 June 2013; Revised 6 August 2013; Accepted 7 August 2013

Academic Editor: Piero Luigi Almasio

Copyright © 2013 Hiroshi Abe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Ganem and A. M. Prince, “Hepatitis B virus infection—natural history and clinical consequences,” The New England Journal of Medicine, vol. 350, no. 11, pp. 1118–1129, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. A. S. F. Lok and B. J. McMahon, “Chronic hepatitis B: update of recommendations,” Hepatology, vol. 39, no. 3, pp. 857–861, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. L. Dienstag, “Drug therapy: hepatitis B virus infection,” The New England Journal of Medicine, vol. 359, no. 14, pp. 1486–1500, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. E. B. Keeffe, D. T. Dieterich, S.-H. B. Han et al., “A treatment algorithm for the management of chronic hepatitis B virus infection in the united states: 2008 update,” Clinical Gastroenterology and Hepatology, vol. 6, no. 12, pp. 1315–1341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. C.-Y. Dai, W.-L. Chuang, M.-Y. Hsieh et al., “Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B,” Antiviral Research, vol. 75, no. 2, pp. 146–151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. C.-L. Lai, R.-N. Chien, N. W. Y. Leung et al., “A one-year trial of lamivudine for chronic hepatitis B,” The New England Journal of Medicine, vol. 339, no. 2, pp. 61–68, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. C.-H. Chen, C.-M. Lee, S.-N. Lu et al., “Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants,” Journal of Hepatology, vol. 41, no. 3, pp. 454–461, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Rapti, E. Dimou, P. Mitsoula, and S. J. Hadziyannis, “Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B,” Hepatology, vol. 45, no. 2, pp. 307–313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. D. J. Tenney, R. E. Rose, C. J. Baldick et al., “Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 3, pp. 902–911, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. European Association for the Study of the Liver, “EASL clinical practice guidelines: management of chronic hepatitis B,” Journal of Hepatology, vol. 50, no. 2, pp. 227–242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Lampertico, M. Viganò, E. Manenti, M. Iavarone, E. Sablon, and M. Colombo, “Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients,” Gastroenterology, vol. 133, no. 5, pp. 1445–1451, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Yatsuji, F. Suzuki, H. Sezaki et al., “Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up,” Journal of Hepatology, vol. 48, no. 6, pp. 923–931, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. K. Fung and A. S. F. Lok, “Drug insight: nucleoside and nucleotide analog inhibitors for hepatitis B,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 1, no. 2, pp. 90–97, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. N. B. Ha, N. B. Ha, R. T. Garcia et al., “Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil,” Hepatology, vol. 50, no. 3, pp. 727–734, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al., “Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B,” The New England Journal of Medicine, vol. 348, no. 9, pp. 800–807, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. S. J. Hadziyannis, N. C. Tassopoulos, E. Jenny Heathcote et al., “Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B,” The New England Journal of Medicine, vol. 352, no. 26, pp. 2673–2681, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Tamori, M. Enomoto, S. Kobayashi et al., “Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus,” Journal of Viral Hepatitis, vol. 17, no. 2, pp. 123–129, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. M. Girgis, T. Wong, M. C. Ngu et al., “Hypophosphataemic osteomalacia in patients on adefovir dipivoxil,” Journal of Clinical Gastroenterology, vol. 45, no. 5, pp. 468–473, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Ureña, M. Hruby, A. Ferreira, K. S. Ang, and M.-C. De Vernejoul, “Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients,” Journal of the American Society of Nephrology, vol. 7, no. 3, pp. 506–512, 1996. View at Google Scholar · View at Scopus
  20. J. A. Whitworth, “2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension,” Journal of Hypertension, vol. 21, no. 11, pp. 1983–1992, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Kuzuya, S. Nakagawa, J. Satoh et al., “Report of the committee on the classification and diagnostic criteria of diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 55, no. 1, pp. 65–85, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. R. B. D'Agostino Jr., “Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group,” Statistics in Medicine, vol. 17, pp. 2265–2281, 1998. View at Google Scholar
  23. M. M. Joffe and P. R. Rosenbaum, “Invited commentary: propensity scores,” American Journal of Epidemiology, vol. 150, no. 4, pp. 327–333, 1999. View at Google Scholar · View at Scopus
  24. S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al., “Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years,” Gastroenterology, vol. 131, no. 6, pp. 1743–1751, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Gara, X. Zhao, M. T. Collins et al., “Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B,” Alimentary Pharmacology and Therapeutics, vol. 35, no. 11, pp. 1317–1325, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Yatsuji, F. Suzuki, H. Sezaki et al., “Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up,” Journal of Hepatology, vol. 48, no. 6, pp. 923–931, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. J. L. Hartono, M. O. Aung, Y. Y. Dan et al., “Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B,” Alimentary Pharmacology & Therapeutics, vol. 37, pp. 710–719, 2013. View at Google Scholar
  28. M. A. Jhaveri, H. W. Mawad, A. C. Thornton, N. W. Mullen, and R. N. Greenberg, “Tenofovir-associated severe bone pain: i cannot walk!,” Journal of the International Association of Physicians in AIDS Care, vol. 9, no. 5, pp. 328–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. C. A. Fux, A. Rauch, M. Simcock et al., “Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study,” Antiviral Therapy, vol. 13, no. 8, pp. 1077–1082, 2008. View at Google Scholar · View at Scopus
  30. Y. Suzuki, F. Suzuki, Y. Kawamura et al., “Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?” Journal of Gastroenterology and Hepatology, vol. 24, no. 3, pp. 429–435, 2009. View at Publisher · View at Google Scholar · View at Scopus